CureVac N.V.

NASDAQ:CVAC   3:59:53 PM EDT
44.00
+0.38 (+0.87%)
Products, Regulatory

CureVac Presents Data From Phase 1 Study Of Oncology Candidate Cv8102

Published: 11/10/2021 12:18 GMT
CureVac N.V. (CVAC) - Presents Promising Data at Sitc From Phase 1 Study of Oncology Candidate Cv8102 Showing Systemic Immune Response.
Expansion Part of Phase 1 Study Fully Recruited; Results Expected in Second Half of 2022.
Immune Profiling of Clinical Trial Participants in Phase 1 Dose-escalation Study Shows Immune Response in Both Injected and Non-injected Lesions.